Abstract
The use of the IFN-γ ELISPOT assay to evaluate cellular immune responses has gained increasing popularity, especially as a surrogate measure for CTL responses. We developed and validated some modifications of the IFN-γ ELISPOT assay to optimize immunological monitoring of various cancer vaccine trials. Taking into consideration that the main mechanism of cell-mediated cytotoxicity is the release of cytolytic granules that contain, among others, cytolytic protein Granzyme B (GrB), we developed the GrB ELISPOT assay. Extensive studies demonstrated that the GrB ELISPOT assay is specific, accurately measures the rapid release of GrB, is more sensitive than the 51Cr-release assay, and that it may be successfully applied to measuring CTL precursory frequency in PBMC from cancer patients. Assuming that immunological assays that demonstrate recognition of native tumor cells (tumor-specific) may be more clinically relevant than assays that demonstrate recognition of tumor protein or peptide (antigen-specific), we developed and validated the Autologous Tumor IFN-γ ELISPOT assay using PBMC from idiotype vaccinated lymphoma patients as effectors and autologous B cell lymphoma tumor cells as targets. The precursor frequency of tumor-reactive T cells was significantly higher in the postvaccine PBMC, compared with prevaccine samples in all patients tested. Furthermore, the specificity of these T cells was established by the lack of reactivity against autologous normal B cells. These results demonstrate the feasibility of evaluating tumor-specific T cell responses when autologous, primary tumor cells are available as targets. Modifications of ELISPOT assay described in this chapter allow more comprehensive assessment of low frequency tumor-specific CTL and their specific effector functions and can provide valuable insight with regards to immune responses in cancer vaccine trials.
Chapter PDF
Key words
References
Rosenberg S. Progress in human tumor immunology and immunotherapy. Nature 2001, 411:380–4.
Finn O, Lotze M. A decade in the life of tumor immunology. Clin Cancer Res 2001, 7:759s–760s.
Kwak L. Translational development of active immunotherapy for hematologic malignancies. Semin Oncol 2003, 30(3 Suppl 8):17–22.
Keilholz U, Weber J, Finke J, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002, 25:97–138.
Regner M, Lobigs M, Blanden R, Mullbacher A. Effector cytolotic function but not IFN-gamma production in cytotoxic T cells triggered by virus-infected target cells in vitro. Scand J Immunol 2001, 54:366–74.
Trinchieri G, Perussia B. Human natural killer cells: biologic and pathologic aspects. Lab Invest 1984, 50:489–513.
Smyth M, Trapani J. Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol Today 1995, 16:202–6.
Podack E. Execution and suicide: cytotoxic lymphocytes enforce Draconian laws through separate molecular pathways. Curr Opin Immunol 1995, 7:11–6.
Berke G. The CTL’s kiss of death. Cell 1995, 81:9–12.
Liu C., Persechini P., Young J. Perforin and lymphocyte-mediated cytolysis. Immunol Rev 1995, 146:145–75.
Jenne D., Tschopp J. Granzymes, a family of serine proteases released from granules of cytolytic T lymphocytes upon T cell receptor stimulation. Immunol Rev 1988, 103:53–71.
Rininsland F., Helms T., Asaad R., Boehm B., Tary-Lehmann M. Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity. J Immunol Methods 2000, 240:143–55.
Shafer-Weaver K, Sayers T., Strobl S., et al. The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med. 2003, 1:14.
Whiteside T. Immunologic monitoring of clinical trials in patients with cancer: technology versus common sense. Immunol Invest 2000, 29:149–62.
Schmittel A, Keilholz U., Thiel E., Scheibenbogen C. Quantification of tumor-specific T lymphocytes with the ELISPOT assay. J Immunother 2000, 23:289–95.
Asai T., Storkus W, Mueller-Berghaus J., et al. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins. Cancer Immun 2002, 2:3.
Malyguine A., Strobl S., Shafer-Weaver K., et al. A Modified Human ELISPOT Assay to Detect Specific Responses to Primary Tumor Cell Targets. J Transl Med 2004, 2:9.
Bendandi M., Gocke C., Kobrin C., et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999, 5:1171–1177.
Derby E., Reddy V., Nelson E., et al. Correlation of human CD56+ cell cytotoxicity and IFN-gamma production. Cytokine 2001, 13:85–90.
J Russell, T Ley. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol. 2002, 20:323–70.
Griffiths G. Protein sorting and secretion during CTL killing. Semin Immunol 1997, 9:109–15.
Henkart P. CTL effector functions. Semin Immunol 1997, 9:85–6
Smyth M, Street S, Trapani J. Cutting Edge: Granzymes A and B are not essential for perforin-mediated tumor rejection. J Immunol 2003, 171:515–518.
Davis J, Smyth M, Trapani J. Granzyme A and B-deficient killer lymphocytes are defective in eliciting DNA fragmentation but retain potent in vivo anti-tumor capacity. Eur J Immunol 2001, 31:39–47.
Sayers T., Wiltrout T., Sowder R., Munger W., Smyth M., Henderson L. Purification of a factor from the granules of a rat natural killer cell line (RNK) that reduces tumor cell growth and changes tumor morphology. Molecular identity with a granule serine protease (RNKP-1). J Immunol 1992, 148:292–300.
Smyth M., Kelly J., Sutton V., et al. Unlocking the secrets of cytotoxic granule proteins. J Leukoc Biol 2001, 70:18–29.
Kwak L., Pennington R, Boni L., Ochoa A., Robb R., Popescu M. Cutting Edge: Liposomal formulation of a self lymphoma antigen induces potent protective anti-tumor immunity. J Immunol 1998, 160:3637–3461.
Schultze J, Cardoso A, Freeman G, et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 1995, 92:8200–8204.
Nuchtern J., Biddison W., Klausner R. Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature 1990, 343:74–6.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer
About this chapter
Cite this chapter
Malyguine, A. (2005). Modified ELISPOT. In: Nagorsen, D., Marincola, F. (eds) Analyzing T Cell Responses. Springer, Dordrecht. https://doi.org/10.1007/1-4020-3623-X_8
Download citation
DOI: https://doi.org/10.1007/1-4020-3623-X_8
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-3622-4
Online ISBN: 978-1-4020-3623-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)